Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CA$ 0.16
Key Takeaways
Risk factor
Considerable default risk
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19)...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is 'cheap' on EV/EBITDA.
Data is available to registered users only
